PL3363439T3 - Kompozycje terapeutyczne do leczenia cukrzycowej polineuropatii symetrycznej - Google Patents

Kompozycje terapeutyczne do leczenia cukrzycowej polineuropatii symetrycznej

Info

Publication number
PL3363439T3
PL3363439T3 PL17206278.8T PL17206278T PL3363439T3 PL 3363439 T3 PL3363439 T3 PL 3363439T3 PL 17206278 T PL17206278 T PL 17206278T PL 3363439 T3 PL3363439 T3 PL 3363439T3
Authority
PL
Poland
Prior art keywords
diabetic
treatment
therapeutic compositions
symmetric polyneuropathy
polyneuropathy
Prior art date
Application number
PL17206278.8T
Other languages
English (en)
Inventor
Paul Fernyhough
Nigel A. Calcutt
Lakshmi Kotra
Original Assignee
University Of Manitoba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Manitoba filed Critical University Of Manitoba
Publication of PL3363439T3 publication Critical patent/PL3363439T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL17206278.8T 2010-10-25 2011-10-24 Kompozycje terapeutyczne do leczenia cukrzycowej polineuropatii symetrycznej PL3363439T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40650210P 2010-10-25 2010-10-25
US201161531803P 2011-09-07 2011-09-07

Publications (1)

Publication Number Publication Date
PL3363439T3 true PL3363439T3 (pl) 2025-09-22

Family

ID=45993001

Family Applications (2)

Application Number Title Priority Date Filing Date
PL11835385T PL2632468T3 (pl) 2010-10-25 2011-10-24 Kompozycje terapeutyczne do leczenia symetrycznej polineuropatii cukrzycowej
PL17206278.8T PL3363439T3 (pl) 2010-10-25 2011-10-24 Kompozycje terapeutyczne do leczenia cukrzycowej polineuropatii symetrycznej

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL11835385T PL2632468T3 (pl) 2010-10-25 2011-10-24 Kompozycje terapeutyczne do leczenia symetrycznej polineuropatii cukrzycowej

Country Status (13)

Country Link
US (3) US10307428B2 (pl)
EP (3) EP4537829A3 (pl)
CN (1) CN103298473B (pl)
CA (1) CA2804797C (pl)
DK (1) DK2632468T3 (pl)
ES (2) ES2655688T3 (pl)
HR (1) HRP20250395T1 (pl)
HU (1) HUE070784T2 (pl)
NO (1) NO2632468T3 (pl)
PL (2) PL2632468T3 (pl)
PT (1) PT2632468T (pl)
RS (1) RS66691B1 (pl)
WO (1) WO2012055018A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2934578A1 (en) * 2013-12-20 2015-06-25 University Of Manitoba Compositions comprising muscarinic m1 receptor antagonists for treatment of non-diabetic peripheral neuropathies
US9743513B2 (en) 2014-12-26 2017-08-22 Industrial Technology Research Institute Flexible electronic device
CA3133646A1 (en) * 2019-03-26 2020-10-01 Winsantor, Inc. Topical formulations for treatment of peripheral neuropathies
US20240316028A1 (en) * 2023-03-16 2024-09-26 Glaukos Corporation Ophthalmic cream formulations and their uses

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6512010B1 (en) * 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
AU753270B2 (en) * 1998-05-21 2002-10-10 Isis Pharmaceuticals, Inc. Compositions and methods for topical delivery of oligonucleotides
US20030104041A1 (en) * 1999-12-16 2003-06-05 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
NZ529615A (en) * 2001-05-25 2005-07-29 Valley Forge Pharmaceuticals Pirenzepine ophthalmic gel
CA2461696A1 (en) * 2001-09-26 2003-04-03 Alison B. Lukacsko Compositions and methods for inhibiting eccrine perspiration in humans
US20090325975A1 (en) * 2005-07-15 2009-12-31 Helmut H Buschmann Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
AR058193A1 (es) * 2005-11-21 2008-01-23 Schering Plough Ltd Composiciones farmaceuticas
CN101472476B (zh) * 2006-06-16 2013-10-30 泰拉科斯有限公司 毒蕈碱型受体m1拮抗剂在制备治疗肥胖症的药物中的应用
US7893053B2 (en) * 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
US8748419B2 (en) * 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
US20080255062A1 (en) * 2007-02-13 2008-10-16 University Of Manitoba Axon regeneration from adult sensory neurons
CN101422610A (zh) * 2007-12-04 2009-05-06 袁才蔚 一种化学药复合物制剂及其应用

Also Published As

Publication number Publication date
DK2632468T3 (en) 2018-02-12
CN103298473A (zh) 2013-09-11
ES3016907T3 (en) 2025-05-12
HRP20250395T1 (hr) 2025-05-23
US11925649B2 (en) 2024-03-12
ES2655688T3 (es) 2018-02-21
EP3363439A2 (en) 2018-08-22
US20240180922A1 (en) 2024-06-06
US20190046540A1 (en) 2019-02-14
EP4537829A2 (en) 2025-04-16
US10307428B2 (en) 2019-06-04
RS66691B1 (sr) 2025-05-30
CA2804797C (en) 2014-12-23
HUE070784T2 (hu) 2025-06-28
CN103298473B (zh) 2015-07-29
WO2012055018A1 (en) 2012-05-03
EP2632468A4 (en) 2014-08-27
PT2632468T (pt) 2018-03-02
EP3363439C0 (en) 2025-01-08
NO2632468T3 (pl) 2018-05-12
EP2632468A1 (en) 2013-09-04
CA2804797A1 (en) 2012-05-03
EP3363439B1 (en) 2025-01-08
EP3363439A3 (en) 2018-12-05
US20130267506A1 (en) 2013-10-10
EP2632468B1 (en) 2017-12-13
EP4537829A3 (en) 2025-06-18
PL2632468T3 (pl) 2018-04-30

Similar Documents

Publication Publication Date Title
CO6930321A2 (es) Curación de tejidos
ZA201403795B (en) Formulations for the treatment of diabetes
ME03042B (me) Jedinjenja i kompozicije za tretman parazitskih oboljenja
LT3470063T (lt) Farmacinės kompozicijos, skirtos cftr nulemtų ligų gydymui
HUE049240T2 (hu) Oxintomodulin analógot tartalmazó készítmény diabetes kezelésére
EP2489334A4 (en) MEDICAL ENDOPROTHESIS
HUE048876T2 (hu) Rákos megbetegedések kezelése
IL229474A0 (en) Cannabinoids for use in the treatment of neuropatich pain
PL2739153T3 (pl) Leczenie raka sutka
PL2582366T3 (pl) Kombinacja farmaceutyczna do leczenia bólu
HUE045367T2 (hu) Kombinált terápia diabétesz kezelésére
PL3443957T3 (pl) Związki i kompozycje stosowane w leczeniu nowotworów
DK2734212T3 (da) Sammensætninger omfattende diclofenac til behandling af postoperativ smerte
CO6801718A2 (es) Composición terapéutica para el tratamiento de glioblastoma
PL2718434T3 (pl) Kompozycje i sposoby leczenia choroby trzewnej
BR112014004434A2 (pt) cateter biocompatível
IL229081A0 (en) Isoxazolines as therapeutic agents
IL227747A0 (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
BR112013003275A2 (pt) composição de tratamento oral
EP2787927A4 (en) EXPANSIONS OF ORTHOPEDIC IMPLANTS
BR112013020339A2 (pt) composição de tratamento de sementes
BR112013015048A2 (pt) composição para o tratamento de distúrbios metabólicos
IL238592B (en) Compounds for treatment of liver diseases
IT1397838B1 (it) Composizione per la cura delle piante
ITRM20120530A1 (it) Compounds for use in the treatment of parasitic diseases